Although patients with progression have elevated NGAL levels, due to the small number of patients, it is not possible to assess the level of impact of the pathological substrate (primary diseases) on the progression of chronic kidney disease and a correlation with NGAL level. This evidence concerns the gene LCN2 and chronic kidney disease.